Introduction
Multiple sclerosis (MS) 1 is a chronic inflammatory disease of the central nervous system (CNS) characterized by a progressive loss of oligodendrocytes and demyelination in the white matter (1) . In the acute stage of disease, lesions contain macrophages, T cells, and immunoglobulin deposits, suggesting that the demyelination process is mediated by the immune system (2) (3) (4) (5) . The inflammatory picture of early lesions, which is followed by a progressive gliosis, also suggested that the pathological process may be initiated by infectious agents and then self-perpetuated by a cross-reactive autoimmune process (6) (7) (8) (9) (10) (11) . Although the antigen(s) driving this self-destructive process in MS has not been identified, the importance of myelin-derived antigens was demonstrated by their abilities to elicit an MS-like demyelinating disease, experimental allergic encephalomyelitis (EAE), in various animal models (1, 12) .
The major difficulties in applying the EAE model to MS stem from a lack of identification of relevant autoantigen(s). Studies on relapsing EAE have shown that different encephalitogenic molecules or epitopes within them are selected that are compatible with the heterogeneity of the immune response in MS, suggesting that disease initiation and relapse episodes are induced by different neuroantigens (13, 14) . Most efforts have been focused on myelin basic protein (MBP) and proteolipid protein that make up as much as 30 and 50% of CNS myelin, respectively (15) . Thus, MBP and proteolipid protein are likely to be prominent targets of an autoimmune response secondary to tissue injury in the CNS. Nevertheless, T cell responses to MBP and proteolipid protein did not differ considerably between MS patients and control donors (1) .
Previous studies from this laboratory, pursuing the goal to isolate autoantigens containing epitopes cross-reactive with viral proteins, demonstrated that an autoantigen, partially encoded by a retrotransposon and selectively expressed in oligodendrocytes at high levels (16) , corresponds to transaldolase (17) , a rate-limiting enzyme of the pentose phosphate pathway (PPP). Although glucose is largely metabolized through the glycolytic pathway and the tricarboxylic acid cycle, the significance of PPP in the brain has long been established. During brain development PPP provides fundamental factors for the biosynthesis of nucleic acids and lipids (18) . The latter is particularly important at the period of active myelination (19, 20) . The overall activity of PPP in the brain declines fivefold from birth to maturity (21) . Whereas under normal conditions only as little as 1% of the glucose is metabolized through the PPP in the brain (22), at times of rapid myelination up to 60% of the glucose used by the brain is metabolized via the PPP linked to the high rate of lipid biosynthesis (23) . Another fundamental function of PPP is to maintain glutathione in a reduced state and thus provide protection of sulfhydryl groups and cellular integrity from emerging oxygen radicals (18) . Oligodendrocyte-specific expression of TAL is possibly linked to production of large amounts of lipids, as a major component of myelin, and protection of the vast network of myelin sheaths from oxygen radicals. In the present study, we show that similar to MBP, transaldolase (TAL) is selectively depleted in demyelinating plaque lesions of MS brains. Patients with MS have an-tibodies to TAL in their blood (29/94) and cerebrospinal fluid (CSF) (16/23), whereas human TAL (TAL-H) antibodies are absent in normal individuals and patients with other autoimmune and neurological diseases (16) . Antibodies to MBP were not found in serum and CSF of MS patients. In addition, TAL-H elicited a skewing of the T cell receptor (TCR) V ␤ repertoire of peripheral blood T lymphocytes from patients with MS in comparison to MBP as a control antigen. These results suggested that TAL-H may be a more significant target than MBP of myelinreactive T cells and of humoral autoreactivity in MS patients.
Methods
Patients and human tissue samples. Patients included 94 with MS and, as controls, 9 patients with other neurological diseases (OND), 10 patients with SLE, and 74 healthy subjects. All patients satisfied the criteria for a definitive diagnosis (24). Patients with MS were diagnosed according to the criteria of Poser et al. (25) . Patients with OND were diagnosed with acute meningitis (1), Parkinson's disease (1), progressive multifocal leukoencephalopathy (1), paresthesias (1), and cerebrovascular disease (5) . Matching CSF and blood samples from patients with MS were kindly provided by Dr. W.W. Tourtelotte from the National Neurological Research Specimen Bank, Veterans Administration Medical Center, Los Angeles, CA. Coronal brain sections from four donors with MS were obtained from the Rocky Mountain Multiple Sclerosis Center, Englewood, CO.
Immunohistochemistry. Formalin-fixed (10% formaldehyde in PBS) and paraffin-embedded sections of human postmortem brain tissue from 10 donors without neurological disorder and from four patients with MS were stained with control 169 preimmune rabbit serum, anti-TAL-H immune rabbit serum 169 (17), anti-MBP rabbit serum, and anti-glial fibrillary acidic protein (GFAP) rabbit serum (DAKO, Glostrup, Denmark) at dilutions of 1:5,000. Slides were developed using biotinylated goat anti-rabbit IgG and alkaline phosphatase-conjugated streptavidin, and substrate (all from DAKO). Neurofilament-specific mAb SMI 312 was obtained from Sternberger Monoclonals (Baltimore, MD).
Antigens and antibodies. Full-length recombinant TAL-H protein was expressed as a fusion protein with glutathione S-transferase (GST) encoded by pGEX-2T plasmid vector (26) , affinity-purified through binding of GST to glutathione-coated agarose beads, cleaved from GST by 1 NIH unit of thrombin (Sigma Chemical Co., St. Louis, MO), and separated from the agarose bead-bound GST by centrifugation (16) . Control GST antigen was prepared by elution from glutathione-coated agarose beads in 10 mM reduced glutathione, 50 mM Tris-HCl, pH 8.0. The purified full-length recombinant TAL-H was analyzed by SDS-PAGE and Western blot and tested for TAL enzyme activity as earlier described (17, 27) . MBP was purified from neurologically normal human brain according to the procedure of , and anti-GFAP rabbit serum (E). Slides were developed using biotinylated goat anti-rabbit IgG or anti-mouse IgG, peroxidase-conjugated streptavidin, and substrate. Section F was counter-stained with hematoxylin. Marked decrease of immunoreactivity with anti-TAL and anti-MBP antibodies and increased staining with anti-GFAP antibody in a defined circular area corresponds to a demyelinating plaque lesion. Magnification, 4. Higher power photographs (ϫ400) of anti-TAL-H antibody-stained section A show absence of oligodendrocyte-specific immunoreactivity in center of the plaque area (G) and staining of oligodendrocytes in adjacent normal white matter (H).
Deibler et al. (28) . Purity of the MBP preparations was analyzed by SDS-PAGE and Western blot. Tetanus toxoid was obtained from Wyeth Laboratories (Marietta, PA). Concanavalin A (Con A) was purchased from Sigma. Highly specific polyclonal rabbit antibodies 169 and 170 directed to the 139 amino acid long NH 2 -terminal segment of TAL-H were developed earlier (17) . Antibody to MBP was obtained from DAKO (Carpinteria, CA).
Western blot analysis. 500 ng recombinant TAL-H protein in 10 l per well was separated by SDS-PAGE and electroblotted to nitrocellulose (29) . Nitrocellulose strips were incubated in 100 mM Tris, pH 7.5, 0.9% NaCl, 0.1% Tween 20, and 5% skim milk with antibodies (at a 1,000-fold dilution unless indicated otherwise) for 1 h at room temperature. For detection of rabbit antibodies, after washing, the strips were incubated with horseradish peroxidase-conjugated goat anti-rabbit IgG (Boehringer Mannheim, Indianapolis, IN). For detection of human antibodies, after washing the strips were incubated with biotinylated goat anti-human serum and, subsequently, with horseradish peroxidase-conjugated avidin (Jackson Laboratories, West Grove, PA). In between the incubations, the strips were vigorously washed in 0.1% Tween-20, 100 mM Tris pH 7.5, and 0.9% NaCl. The blots were developed with a substrate comprised of 1 mg/ ml 4-chloronaphthol and 0.003% hydrogen peroxide.
Testing of TAL enzyme activity. TAL enzyme activity was measured by the transfer of the dihydroxyacetone three-carbon unit from the donor d -fructose-6-phosphate, to the acceptor d -erythrose-4-phosphate (27) . Enzyme activity was assayed in the presence of 3.2 mM D -fructose 6-phosphate, 0.2 mM D -erythrose-4-phosphate, 0.1 mM NADH, 10 g ␣ -glycerophosphate dehydrogenase/triosephosphate isomerase at a 1:6 ratio in 1 ml phosphate buffered saline, pH 7.4, at room temperature by continuous absorbance reading at 340 nm for 20 min. The assay was conducted in the activity range of 0.001-0.01 U/ml.
Stimulation of PBL. PBMC were isolated from heparinized venous blood on Ficoll-Hypaque gradient and resuspended in RPMI 1640 medium, supplemented with 10% FCS, 2 mM l -glutamine, 100 IU/ml penicillin, and 100 g/ml gentamicin. 10 5 cells were incubated in each well of a microtiter plate using six parallel samples. Concentration ranges of 1-30 g/ml for TAL-H and 1-100 g/ml for MBP were tested. 5 g/ml for TAL-H and 30 g/ml for MBP were found to be optimal to induce cell proliferation. Negative control and positive control cultures (containing 10 g/ml Con A or 10 g/ml tetanus toxoid) were included in each experiment. 5 g/ml affinity-purified GST was used as a negative control antigen. The plates were incubated at 37 Њ C in a humidified atmosphere with 5% CO 2 for 72 h. The cultures were pulsed with 0.4 Ci 3 H-TdR 8 h before termination. Cells were harvested and 3 H-TdR incorporation was measured as earlier described (30) . The results were expressed in counts per min as mean Ϯ standard error (SE) of six parallel cultures. Stimulation indices (SIs) are given as mean Ϯ SD of n experiments. Mean values ( Ϯ SD) were compared using Student's t test. Correlations were analyzed by linear regression. P values Ͻ 0.05 were considered significant (31) .
Analysis of the TCR V ␤ repertoire by reverse-transcriptase (RT)-PCR.
Total cellular RNA was isolated from cultured cells by the RNAzol method (32). 3 g of RNA was reverse transcribed into cDNA with oligo-dT primer by 200 U of Superscript reverse transcriptase according to the manufacturer's protocol (GIBCO-BRL, Bethesda, MD). For analysis of TCR V ␤ gene usage, cDNA aliquots were subjected to PCR using 24 V ␤ sense strand-specific oligonucleotides in combination with an antisense strand-specific C ␤ primer (C ␤ REVF, 5 Ј -CGGGCTGCTCCTTGAGGGGCTGCG-3 Ј ) (33) . As an internal control, each PCR reaction included C ␣ -specific sense (C ␣ -FWJ, 5 Ј -CCCTGACCCTGCCGTGTACCAGCT-3 Ј ) and antisense primers (C ␣ REVE, 5 Ј -GTTGCTCCAGGCCGCGGCACT-GTT-3 Ј ) (33) . Amplifications were carried out in 30 cycles at a denaturing temperature of 94 Њ C (1 min), annealing at 60 Њ C (1 min), and extension at 72 Њ C (2 min). Amplified products were analyzed by electrophoresis in 2% agarose gel, transferred to Zetabind membrane (Bio-Rad, Richmond, CA) in 0.4 N NaOH, and hybridized to an internal
responding to positions 128-106 in the C ␤ 2 gene) primers (33) . Blots were exposed to phosphor storage screen and analysed using a computerized phosphorimager (Molecular Dynamics, Sunnyvale, CA). All signals for the 24V ␤ families together were scored as 100%. Data show mean of duplicate analyses. In accordance with previous data (34), repeated antigen stimulation and RT-PCR analyses of the TCR V ␤ repertoire consistently gave variations Ͻ 10% in use of individual V ␤ gene families.
Results

Selective loss of MBP and TAL-H in MS plaques.
Immunohistochemical analysis of postmortem sections revealed that expression of TAL-H is specific for oligodendrocytes in the human brain (16) . Localization of TAL-H to oligodendroglia was confirmed by parallel staining for MBP and galactocerebroside (which showed concordant staining pattern with TAL-H) and GFAP (which showed astrocyte-specific discordant staining pattern relative to TAL-H). Since demyelination in MS results from damage to oligodendrocytes, presence of TAL-H in MS brain sections was investigated. Concordant loss of TAL-H and MBP within demyelinating lesions was noted in parallel sections from the brain of a 38-yr-old female with an 8-yr history of MS (MS3/H) using TAL-H specific rabbit antibody 169 and an MBP-specific rabbit antibody, respectively (Fig. 1, A and B ). As a negative control, parallel sections were simultaneously stained with 169 preimmune rabbit serum (Fig. 1 C ) . Maintenance of axons and increased expression of GFAP within the plaque area was visualized by staining with neurofilament-specific mAb SMI 312 and a GFAP-specific rabbit antibody, respectively (Fig. 1, D and E ) . Absence of oligodendrocyte-specific immunoreactivity in center of the plaque area ( Fig. 1 G ) and staining of oligodendrocytes in adjacent normal white matter with anti-TAL-H antibody are shown in Fig. 1 H. Similar findings were obtained in three additional MS brain specimens (MS1/C, MS2/R, and MS3/M; not shown). destroyed in patients with MS by an oligodendrocyte-specific immune-mediated process. Recognition of oligodendroglial autoantigens, TAL-H and MBP, was investigated by antibodies in sera from 94 patients with MS, 10 patients with SLE, 9 patients with OND, and 74 control blood donors. TAL-H-specific seropositivity was based on immunoreactivity to recombinant protein (500 ng/lane) at serum dilutions of 1:100 or higher using Western blot analysis. Enzymatic activity and purity of each recombinant (r)TAL-H preparation was controlled by SDS-PAGE and Western blot (Fig. 2) . In accordance with earlier data (16), presence of TAL-H autoantibodies was highly specific for MS. TAL-specific antibodies were detected in 29/ 94 patients with MS. TAL antibodies were not detectable in patients with SLE, OND, or in control donors. Representative data are shown in Fig. 2 . Thus, detection of TAL-H autoantibodies in patients with MS is a highly significant finding as compared to control and other autoimmune disease groups ( P Ͻ 0.001, using chi-square test). No correlation was found between TAL-H seropositivity and immunoglobulin concentrations in the sera of seven patients with MS and four control donors (data not shown).
Presence of antibodies to TAL-H and absence of antibodies to MBP in patients with MS. Oligodendrocytes are selectively
Humoral autoreactivity to TAL-H was compared to that against MBP purified from neurologically normal human brain according to the procedure of Deibler et al. (28) . Purity of the MBP preparations was analyzed by SDS-PAGE and Western blot. The MBP antigen used was essentially free from other brain proteins and no immunological cross-reactivity between MBP and TAL-H was observed (Fig. 2) . In contrast to TAL-H, antibodies to MBP were absent in all MS sera tested at a dilution of 1:100 using 500 ng of purified human MBP antigen per lane (representative results are shown in Fig. 3 ).
Most patients with MS have a disease course characterized by relapses and remissions, termed relapsing/remitting MS. A minority of patients have a primarily chronic progressive disease. Many of the R/R patients will, nevertheless, eventually enter a phase of secondary progressive evolution of symptoms. TAL-H immunoreactivity of sera from seven antibody-positive and eight antibody-negative patients was sequentially tested and gave identical results on two different occasions 6 mo apart. Representative results are shown in Fig. 4 . This suggested that TAL-H seroreactivity is a stable marker in a subset of patients with MS. Western blot reactivity to rTAL-H (38 kD) was sequentially tested in 100-fold diluted sera from patients JAB, TEV, KUB, LAK, and JWA. I, first sample; II, second sample 6 mo later. CON, negative control human serum; 169, rabbit antibody to TAL-H. previous data showing that MBP-specific immunity in MS is primarily T cell mediated (1, 35) . Thus, in comparison to MBP, TAL-H is a prominent target of humoral autoreactivity in MS.
Detection of antibodies to TAL-H but not to MBP in CSF of
Stimulation of PBL proliferation by TAL-H. It is generally accepted that autoreactive T cells in patients with MS recognize oligodendroglial antigens (1). To investigate whether
TAL-H may be a target of autoreactive T cells, its effect on proliferation of PBL was evaluated. Highly purified recombinant TAL-H antigen was used in these studies to ensure that the responses detected were not directed to any other myelin protein. Addition of 5 g/ml TAL-H significantly increased proliferation of lymphocytes from 25 patients with MS (P Ͻ 0.001). The SI varied between 0.8 and 6.5-fold among the patients (Fig. 6 ). Lymphocytes were incubated in the presence of 10% autologous serum. Heat inactivation of autologous serum or use of 10% FCS had no significant effect on the proliferative responses to TAL-H. By contrast, proliferation of lymphocytes from normal donors or patients with SLE was not significantly increased in the presence of TAL-H. 5 g/ml rTAL-H was repeatedly found to be a significantly more po- tent stimulator of lymphocyte proliferation than 30 g/ml MBP (P Ͻ 0.001; Fig. 6 A) . At these optimal concentrations (5 g/ml TAL-H and 30 g/ml MBP), TAL SI Ն 2 was noted in 14/25 patients ( Fig. 6 B and Table I ) whereas MBP SI Ն 2 was noted in 4/25 patients with MS. TAL-H concentrations higher than 5 g/ml (10 and 30 g/ml) and MBP concentrations higher than 30 g/ml (50 and 100 g/ml) resulted in no further increase of T cell proliferation. Affinity-purified recombinant GST expressed from the pGEX-2T vector also failed to stimulate lymphocyte proliferation. No differences in proliferative responses to 10 g/ml tetanus toxoid were observed among the donor groups investigated (not shown).
Previous studies suggested that the frequency of MBPreactive T cells was increased among in vivo-activated IL-2-responsive T cells (36) . To compare the reactivity to TAL-H with that to MBP by in vivo-activated T cells, proliferative responses were evaluated in the presence of human recombinant IL-2. H-TdR incorporation was increased by IL-2 5.2Ϯ0.6-fold in control donors, 3.8Ϯ0.5-fold in patients with MS, and 1.9Ϯ0.5-fold in patients with SLE. Thus, in accordance with earlier data (37), responsiveness to IL-2 was significantly impaired in patients with SLE (P Ͻ 0.001). Proliferation of IL-2-stimulated cells was further increased by rTAL-H in patients with MS (P Ͻ 0.001). MBP had no significant effect on proliferation of IL-2-stimulated cells in any of the donor groups investigated.
In patients with MS, SIs in response to TAL-H ranged from 0.8-6.5-fold, whereas SIs in response to MBP ranged from 0.7-3.0-fold (Fig. 6 B) . Proliferative responses to TAL were generally twofold increased in comparison with those to MBP (P Ͻ 0.001). Additionally, a significant covariance in the extent of TAL-and MBP-induced stimulations was noted in patients with MS (P Ͻ 0.001). Patients with high responsiveness to TAL-H also showed high responsiveness to MBP and donors with low TAL-induced proliferation showed low MBPinduced proliferation as well. No such correlation was observed in control and SLE donors.
Cell proliferation was stimulated twofold or more by TAL-H in 14/25 patients with MS (Table I ). Antibodies to TAL-H were more prevalent in patients with SI Ն 2 (11/14) in comparison to patients with SI Յ 2 (3/11; P Ͻ 0.05). Correlation of celland antibody-mediated immune responses may also indicate sensitization of the immune system to the normally sequestered TAL antigen in a subset of patients with MS. Duration, type, or activity of disease or age of onset did not correlate with T cell responses or antibody production against TAL.
Skewing of TCR V␤ gene usage in response to TAL-H in patients with MS. The repertoire of TCR V␤ genes used by
PBLs in response to stimulation by TAL-H was investigated in two healthy control donors (ALE and STR) and six patients with MS (MAD, AAB, PCA, TEV, PET, and JAB). PBMC were cultured without antigenic stimulation and in the presence of TAL-H (5 g/ml), MBP (30 g/ml), or Con A (5 g/ ml) in parallel for 7 d. Total cellular RNA was isolated from cultured cells by the RNAzol method (32). 3 g of RNA was reverse transcribed into cDNA with oligo-dT primer by 200 U of reverse transcriptase and cDNA aliquots were subjected to PCR using 24 V␤ sense strand-specific oligonucleotides in combination with an antisense strand-specific C␤ primer, C␤REVF. As an internal control, each PCR reaction included C␣-specific sense (C␣-FWJ) and antisense primers (C␣REVE). Amplified products were electrophoresed in 2% agarose gel, transferred to Zetabind membrane in 0.4 N NaOH, and hybridized to internal end-labeled C␣ (C␣REVC) and C␤ primers (C␤REVB). Blots were exposed to x-ray film and analyzed using a computerized automated densitometer. All signals for the 24 V␤ families together were scored as 100%. RT-PCR analyses repeated on two occasions gave similar results. In healthy donors the TCR V␤ repertoire displayed a relatively even distribution among the 24 gene families examined (Fig.  7) . No single gene segment comprised Ͼ 7% of the total T cell compartment in normal donors ALE or STR. By contrast, the TCR V␤ repertoire was less evenly distributed in unstimulated PBL of MS patients. Upon stimulation by TAL-H, skewing in representation of any TCR V␤ families was less than twofold in healthy controls (Fig. 7) . However, stimulation by TAL-H resulted in a twofold or greater expansion of T cells bearing 15 different TCR V␤ gene segments in the six MS patients studied (Table II) . This analysis revealed a diversity of TCR V␤ usage in response to TAL-H. No such shifts in TCR V␤ usage attributable to MBP or Con A were observed in the patients or controls (not shown). V␤ families showing greater than twofold relative expansion in response to TAL-H are cumulatively shown in Table II . Of note, the more profound skewing of the TCR V␤ repertoire was found in patients with the higher proliferative responses to TAL-H (TEV, SI ϭ 6.5; PET, SI ϭ 5.0; JAB, SI ϭ 4.0). Usage of V␤ 4 and V␤ 6 was increased ‫ف‬ 20- fold, whereas that of V␤ 8 was stimulated 65-fold in TEV (Fig.  7 F) . Whereas fold increases were more moderate in PET and JAB than in TEV, the absolute contributions of certain V␤ genes were as high as 36.7% (V␤5 in PET, Fig. 7 G) and 22.8% (V␤2 in JAB, Fig. 7 H) . V␤ families expanded more than twofold in the presence of TAL-H made up as much as 32.2, 36.74, and 59.8% of the total TCR V␤ repertoire in patients JAB, PET, and TEV, respectively (Table II) .
Discussion
In this study, we comparatively analyzed antibody-and T cellmediated immune responses to oligodendroglial autoantigens TAL and MBP in patients with MS. In view of its activity to elicit EAE in various animal models, MBP, which comprises 30% of CNS white matter, has been regarded as the prime candidate autoantigen potentially responsible for triggering pathogenic immune responses in MS (1). However, our present analysis shows that a quantitatively less abundant protein, TAL, comprising ‫ف‬ 0.1-0.5% of the total protein content of oligodendrocytes (data not shown), may be at least as important an antigen as MBP. Indeed, antibodies to affinity-purified rTAL-H were found in 29/94 sera and in 16/23 CSF samples from patients with MS. While the amount of TAL-H antibodies was 5-10-fold lower in the CSF than in sera of corresponding patients, the concentration of TAL-H antibodies based on the total Ig content was enriched 50-100-fold in the CSF. An overall higher prevalence of TAL-H antibodies in the CSF compared with the sera also suggests that these antibodies may be locally produced at least in some of the patients. By contrast, under identical conditions antibodies to MBP were undetectable in sera or CSF from any of the patients with MS. However, it is possible that antibodies solely recognizing conformation-dependent epitopes remained undetected in Western blot analyses. Moreover, proliferative responses to TAL were significantly increased in comparison to MBP in patients with MS. In the presence of IL-2, proliferative responses were further increased in MS patients by TAL, suggesting that TAL-reactive cells may be activated in vivo in patients with MS (36) . These findings are suggestive of the notion that TAL is a more potent immunogen than MBP in MS. Antibodies to TAL were more prevalent in patients with SI Ն 2 (11/14) in comparison with patients with SI Յ 2 (3/11; P Ͻ 0.05). Correlation of cell-and antibody-mediated immune responses, which was observed in serial studies of the patients, may also indicate sensitization of the immune system to the normally sequestered TAL antigen in a subset of patients with MS. Individual variations in the extent of SIs and titers of TAL-specific antibodies are likely to reflect differences in (a) prior exposures to environmental factors and (b) genetic determinants influencing antigen recognition and persistence of autoimmune responses in MS (1, 12) . An association was also noted between SIs in response to TAL and the more moderate proliferative responses to MBP. This correlation may reflect concurrent sensitization with TAL and MBP, perhaps secondary to destruction of oligodendrocytes in MS. Further, in accordance with a concurrent loss of MBP and TAL, immunohistochemical studies of four postmortem MS brain sections demonstrated loss of staining with MBP and TAL antibodies in demyelinating lesions. These findings were consistent with previous studies revealing that similar to MBP, TAL is expressed at selectively high levels in oligodendrocytes in the human brain (16) . Duration of disease or age of onset did not appear to be factors influencing T cell responses or antibody production against TAL. In fact, high titer antibodies and T cell responses were also detectable in a patient with acute MS (ROB , Table II) . Neither humoral nor cell-mediated immunoreactivities to TAL varied with disease type or disease activity, suggesting that autoreactivity to TAL may indeed reflect a state of sensitization against the antigen and could thus serve as a stable marker of the disease. Early appearance and persistence of TAL reactivity may be compatible with an initiating role for immune recognition of TAL in the triggering phase and/or relapses of MS. These possibilities are particularly intriguing based on amino acid sequence homologies and immunological cross-reactivities between TAL and core proteins of human retroviruses (16) . Catalytic activity of rTAL-H was also inhibited in the presence of purified Igs from MS patients ALV and LAK. These data demonstrated that high affinity autoantibodies from patients with MS recognized not only the immunoblotted fulllength TAL-H protein and its NH 2 -terminal fragment (16) but functionally relevant COOH-terminal epitopes as well (38) . The presence of autoantibodies to multiple TAL-H epitopes and the enzyme inhibitory capacity of a subset of autoantibodies suggests that the intact TAL-H protein has become the source of antigenic drive in these patients. This points to a loss of tolerance as the fundamental lesion in TAL-H-specific autoimmunity in MS. Thus, molecular mimicry between a foreign and self-protein which is usually considered as an initiating factor in autoimmunity (16) may lead to an expanded autoimmune response against the entire molecule (39).
Use of the TCR V gene repertoire and its role in mediating demyelination in MS is a controversial issue. Involvement of the TCR in disease pathogenesis was suggested by overrepresentation of a polymorphic HindIII site in the TCR ␤ chain locus (40) and skewing of TCR ␣-chain polymorphisms in MS patients (41) . A skewed TCR V␣ usage in genetically identical twins with MS pointed towards the importance of exogenous factors in shaping both the TCR repertoire and the disease process (42, 43) . In accordance with these findings, in this study a significant skewing of the TCR V␤ repertoire was also observed in unstimulated PBL of all six MS patients as compared to controls. While there was no significant overlap among reports on TCR usage by MBP-specific T cells from peripheral blood of MS patients as recently reviewed (1), two independent studies showed a preferential usage of TCR V␤5.2 and V␤6.1 by MBP-reactive peripheral T cells (44) and relative overexpression of TCR V␤5.2 and V␤6 in MS plaques (45, 46). However, it has become clear that as a general rule TCR V gene usage in MS may not be so limited (47) (48) (49) (50) . In the present study, upon stimulation by TAL-H, T cells bearing 15 distinct TCR V␤ gene segments were found to be expanded to different extent, suggesting an overall diversity of TCR V␤ usage in response to TAL-H in MS patients. Use of individual TCR V␤ segments in response to MBP was increased less than twofold in patients with MS. Whereas skewing of any V␤ in response to TAL-H was also less than twofold in healthy controls, usage of V␤ 1, 2, 3, 4, 5, 6, 8, 9, 10, 11, 14, 15, 18, 20, and 22 were differentially increased ranging from 2.5-65.9-fold with TAL-H-reactive V␤ families making up as much as 21 to 59% of the TCR V␤ repertoire in patients with MS. Profound skewing of a diverse repertoire of TCR V␤ genes in response to stimulation with TAL may represent a primarily antigen driven polyclonal immune response and a state of sensitization to the immunogen. In summary, the data suggest that autoreactivity to TAL may be of pathogenetic and diagnostic significance in a subset of patients with MS.
